Experimental combo targets STK11-Deficient lung cancer
NCT ID NCT06219174
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 1/2 trial tests whether adding difluoromethylornithine (DFMO) to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change (STK11/LKB1 deficiency). About 45 participants will receive the combination. The study aims to find the best dose and measure tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Difluoromethylornithine (DFMO) combined with pembrolizumab (Keytruda)
What this could lead to
If successful, this could offer a new treatment option for a hard-to-treat form of lung cancer that lacks the STK11 gene.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply broadly. The study is currently suspended, and the combination may cause side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States